Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Citalopram. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel process for cyanophthalide using sequential Grignard reagents offers safer, scalable route for antidepressant API manufacturing.
Discover the advanced preparation method for Citalopram intermediates described in patent CN1550497A, offering enhanced safety and cost reduction in pharmaceutical manufacturing.
Patent CN1133633C details a streamlined one-step Grignard route for Citalopram, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturers.
Patent CN101607951A reveals a high-yield Mitsunobu cyclization for Escitalopram. Discover cost-effective manufacturing and superior optical purity for pharmaceutical supply chains.
Patent CN1423643A reveals a novel dehydration route for 5-cyanophthalide, offering significant cost reduction in API manufacturing and enhanced supply chain reliability for antidepressant production.
Patent CN1161350C reveals a novel route for citalopram intermediates, offering significant cost reduction and supply chain reliability for pharmaceutical manufacturing partners globally.
Patent CN101203614A reveals a novel EDTA-complexed enzymatic resolution for high-purity S-escitalopram, offering scalable cost reduction in API manufacturing.
Patent CN1211377C reveals a novel catalytic cyanation method for citalopram intermediates, offering high purity and reduced processing steps for pharmaceutical supply chains.
Discover the novel Grignard-based synthesis of Nitalapram intermediates avoiding toxic cuprous cyanide. A cost-effective, scalable solution for pharmaceutical manufacturing.
Deep dive into CN104072390B. Advanced impurity control for S-escitalopram. Reliable supply chain and cost-effective manufacturing solutions for global pharma.
Patent CN105732249A details a high-ee Rh-catalyzed route for Escitalopram intermediates. This report analyzes cost reduction and supply chain reliability for pharmaceutical manufacturing.
Patent CN102952106A reveals high purity Escitalopram Impurity C synthesis. Offers stable reproducibility and cost reduction in pharmaceutical intermediates manufacturing for global supply chains.
Advanced enzymatic and chemical separation process for high-purity escitalopram intermediates. Reduces manufacturing costs and improves supply chain reliability for global API producers.
Patent CN1761658A details a novel solubility-based purification for 1-(4-fluorophenyl)-1,3-dihydro-5-isobenzofurancarbonitrile, ensuring superior supply chain reliability.
Novel patent CN104725335B details high-purity Escitalopram Hydrobromide synthesis. Offers significant cost reduction and supply chain reliability for pharmaceutical manufacturing partners.
Patent CN1729164A details advanced purification for citalopram diol intermediates offering cost reduction and supply chain reliability for pharmaceutical manufacturing.
Discover the novel CN1556800A process for Citalopram HBr. Achieve >99.7% purity via crystalline salt isolation and SMB chromatography for reliable pharmaceutical intermediate supply.
Patent CN104262306B reveals a superior ketone-based cyclization for Citalopram. Discover how this method reduces solvent waste and boosts yield for reliable API intermediate supply.
Patent CN101048396A details a mild cyclization method for citalopram and escitalopram, offering high purity and scalable manufacturing for reliable pharmaceutical intermediate suppliers.
Patent CN102796065A details a novel resolution and cyclization route for S-escitalopram, offering superior optical purity and simplified manufacturing for global pharmaceutical supply chains.